VSTM - Verastem, Inc.
| Previous Close | 4.1300 |
| Open | 4.1100 |
| Bid | 4.07 x 2200 |
| Ask | 4.20 x 1400 |
| Day's Range | 4.0100 - 4.2500 |
| 52 Week Range | 2.7700 - 10.3500 |
| Volume | 1,867,294 |
| Avg. Volume | 2,879,401 |
| Market Cap | 298.855M |
| Beta (3Y Monthly) | 4.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.39 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.64 |
- Business Wire•9 days ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 83,978 shares of its common stock to four employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $5.21 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on December 3, 2018 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.
- Business Wire•11 days ago
Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting
Multiple Clinical Data Presentations Highlighting Updated Long-Term Follow-Up from the Phase 3 DUO and the DUO Crossover Extension Studies
- Business Wire•11 days ago
Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced an oral presentation highlighting new clinical data from an investigator sponsored trial, led by Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center (MSK), evaluating duvelisib in combination with romidepsin in patients with relapsed or refractory T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) at the American Society of Hematology (ASH) 2018 Annual Meeting, taking place December 1-4, 2018, in San Diego. Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma.
- GlobeNewswire•12 days ago
New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•16 days ago
Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?
Is (VSTM) Outperforming Other Medical Stocks This Year?
- Business Wire•last month
Verastem Oncology Reports Third Quarter 2018 Financial Results
Quarter Highlighted by FDA Approval of COPIKTRA™ Capsules
- Business Wire•last month
Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a collaboration with The Leukemia & Lymphoma Society® (LLS), to accelerate the development of duvelisib for the treatment of patients with peripheral T-cell lymphoma (PTCL), an aggressive type of non-Hodgkin lymphoma (NHL). Verastem Oncology’s duvelisib was selected for the LLS’s Therapy Acceleration Program® (TAP) which provides additional resources to support the development of therapies for patients with blood cancers.
- Business Wire•last month
Verastem Oncology Announces Presentation of Preclinical Data Supporting Dual PI3K-delta and PI3K-gamma Inhibition in Combination with Immunotherapy at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a poster presentation of preclinical data by Jonathan Pachter, Ph.D., the Company’s Chief Scientific Officer, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting being held November 7-11, 2018, in Washington, D.C. “We have assessed the activity of duvelisib, our orally-administered dual inhibitor of PI3K-delta and PI3K-gamma, in combination with either immune checkpoint or co-stimulatory antibodies in syngeneic antitumor models,” said Dr. Pachter. “Results to be presented at SITC’s 33rd Annual Meeting demonstrated that duvelisib shows strong anti-tumor synergy with PD-1 or OX40 antibodies.
- Business Wire•last month
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 6,153 shares of its common stock to one new employee and 40,000 restricted stock units (RSUs) to another new employee. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $5.18 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on November 1, 2018 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.
- ACCESSWIRE•last month
Cannabis and Biotech Firms Making Investors Boatloads
HENDERSON, NV / ACCESSWIRE / November 1, 2018 / With so many opportunities at excellent entry points we decided highlighting one of the more interesting companies on the market, Endonovo Therapeutics, Inc. (ENDV). There are several other diseases the Sofpulse might help with including counteracting the effects of nonalcoholic steatohepatitis (NASH). In a pre-clinical study, one to 2 weeks of treatment with Sofpulse®, the non-invasive proprietary device of Endonovo Therapeutics, appeared to counteract several of the disease signs associated with NASH-associated liver damage.
- Business Wire•last month
Verastem Oncology Announces Data Presentations at the American Society of Hematology 2018 Annual Meeting
− Clinical Study Evaluating the Use of Duvelisib in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma to be Highlighted in an Oral Presentation −
- Zacks•2 months ago
What's in Store for Verastem (VSTM) This Earnings Season?
On Verastem's (VSTM) third-quarter conference call, investor focus will be on the company's launch and reimbursement plans for its newly approved leukemia drug Copiktra.
- GlobeNewswire•2 months ago
New Research Coverage Highlights Zoetis, TripAdvisor, The Gap, Unit, WestRock, and Verastem — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•2 months ago
Verastem Oncology Announces Executive Leadership Appointments and Changes
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the appointment of Ironwood Pharmaceuticals, Inc.’s Chief Financial Officer Gina Consylman to its Board of Directors. Ms. Consylman, who will also serve as the Chair of the Board’s Audit Committee, replaces Louise Phanstiel who is leaving the Board to pursue other professional opportunities.
- ACCESSWIRE•2 months ago
A Stock to be "Aware of" for Liver Cancer Awareness Month
HENDERSON, NV / ACCESSWIRE / October 18, 2018 / October is Liver Cancer Awareness month. According to the American Cancer Society, liver cancer incidence has more than tripled since 1980, liver cancer death rates have increased by almost 3% per year since 2000 and more than 700,000 people are diagnosed with liver cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year.
- Motley Fool•2 months ago
Here's Why Verastem Dropped Precipitously Today
Convertible notes issued by the biotech will dilute investors.
- Business Wire•2 months ago
Verastem Oncology Announces Pricing of Registered Direct Offering of $150 Million of Convertible Notes
Verastem, Inc., (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the pricing of an offering of 5.00% Convertible Senior Notes due 2048 (the Convertible Notes) through a registered direct offering. The aggregate principal amount of Convertible Notes to be sold in the offering is $150 million. The Convertible Notes will be unsecured, will bear interest at a rate of 5.00% per annum, paid semi-annually in arrears, and will mature on November 1, 2048, unless earlier converted, redeemed or repurchased in accordance with their terms prior to such date.
- ACCESSWIRE•2 months ago
Cannabis and Biotech Stocks That Are Set to Explode!
HENDERSON, NV / ACCESSWIRE / October 11, 2018 / With the broader market tanking it is likely investors will find safe haven in cannabis and biotech stocks because they are both innovative sectors. An incredibly ...
- Business Wire•2 months ago
National Comprehensive Cancer Network® Adds Verastem Oncology’s COPIKTRA™ (duvelisib) Capsules to Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Verastem, Inc. , focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network® added COPIKTRA™ capsules to the Clinical Practice Guidelines in Oncology for chronic lymphocytic leukemia/small lymphocytic lymphoma .
- GuruFocus.com•2 months ago
Weekly CEO Buys Highlight
Details the CEO buys this past week from the following companies: Barings BDC and Verastem
- Business Wire•2 months ago
National Comprehensive Cancer Network® Adds Verastem Oncology’s COPIKTRA™ (duvelisib) Capsules to Clinical Practice Guidelines in Oncology
Verastem, Inc. , focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network® added COPIKTRA™ capsules to the Clinical Practice Guidelines in Oncology for follicular lymphoma .
- Business Wire•2 months ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to purchase an aggregate of 193,980 shares of Verastem Oncology's common stock and 50,000 restricted stock units (RSUs) to one new employee. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
- Business Wire•2 months ago
Verastem Oncology Announces Publication of the Phase 3 DUO Study Results in the Journal Blood
Verastem, Inc. , focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the results of the Phase 3 DUO™ study, which evaluated COPIKTRA™ capsules versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma , was published online in the peer-reviewed journal Blood.
- ACCESSWIRE•2 months ago
These Stocks Are on The Brink of Breakouts
While it may be a little late on VSTM, there is another company working on a solution to the same cancers that has made impressive progress recently and could be the next major success story in the sector, Propanc Biopharma, Inc. (PPCB). PPCB is an intriguing biotech firm, that erupted for over 7000% last month going from a low of $0.0039 to a high of over $0.28, the stock is still holding a substantial gain as of the close on Wednesday. PPCB may start receiving increased attention from the street at any moment.
- TheStreet.com•3 months ago
Verastem Could Be Purchased After a Test of the 200-Day Average Line
Buyer beware this is a risky investment. In this daily bar chart of VSTM, below, we can see that prices have made an impressive rally from early April as prices moved from just $3 to briefly over $10. Prices are still above the rising 200-day line.
